Literature DB >> 19663778

Regulation and importance of the PI3K/Akt/mTOR signaling pathway in hematologic malignancies.

Kiyotaka Kawauchi1, Toshie Ogasawara, Masako Yasuyama, Kuniaki Otsuka, Osamu Yamada.   

Abstract

Phosphatidylinositol 3-kinase (PI3K), a heterodimeric lipid kinase, is a key enzyme in signal transduction from various stimuli to downstream pathways that elicit diverse responses involving growth, proliferation, survival, differentiation, and metabolism in many cellular systems. Activated PI3K generates phosphatidylinositol-3,4,5-triphosphate, which recruits phosphatidylinositol-dependent kinase 1 (PDK1) and Akt serine/threonine kinase at the plasma membrane, resulting in activation of Akt. In turn, Akt activates multiple downstream targets, most notably the mTOR pathway. There is abundant evidence implicating the PI3K/Akt/mTOR pathway in the development and progression of a variety of tumors including hematologic neoplasms. Therefore, this pathway is considered a critical target for cancer therapy. We review the regulatory mechanisms of the PI3K/Akt/mTOR signaling pathway and the role of this pathway in oncogenesis of hematological malignancies.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19663778     DOI: 10.2174/187152009789377772

Source DB:  PubMed          Journal:  Anticancer Agents Med Chem        ISSN: 1871-5206            Impact factor:   2.505


  12 in total

1.  Three-arm, randomized, phase 2 study of carboplatin and paclitaxel in combination with cetuximab, cixutumumab, or both for advanced non-small cell lung cancer (NSCLC) patients who will not receive bevacizumab-based therapy: An Eastern Cooperative Oncology Group (ECOG) study (E4508).

Authors:  Nasser H Hanna; Suzanne E Dahlberg; Jill M Kolesar; Charu Aggarwal; Fred R Hirsch; Suresh S Ramalingam; Joan H Schiller
Journal:  Cancer       Date:  2015-03-04       Impact factor: 6.860

2.  Degrasyn potentiates the antitumor effects of bortezomib in mantle cell lymphoma cells in vitro and in vivo: therapeutic implications.

Authors:  Lan V Pham; Archito T Tamayo; Changping Li; William Bornmann; Waldemar Priebe; Richard J Ford
Journal:  Mol Cancer Ther       Date:  2010-07-06       Impact factor: 6.261

3.  A Phase I and Surgical Study of Ribociclib and Everolimus in Children with Recurrent or Refractory Malignant Brain Tumors: A Pediatric Brain Tumor Consortium Study.

Authors:  Mariko D DeWire; Christine Fuller; Olivia Campagne; Tong Lin; Haitao Pan; Tina Young Poussaint; Patricia A Baxter; Eugene I Hwang; Andrew Bukowinski; Kathleen Dorris; Lindsey Hoffman; Angela J Waanders; Matthias A Karajannis; Clinton F Stewart; Arzu Onar-Thomas; Maryam Fouladi; Ira J Dunkel
Journal:  Clin Cancer Res       Date:  2021-02-05       Impact factor: 12.531

4.  Garlic Oil Suppressed Nitrosodiethylamine-Induced Hepatocarcinoma in Rats by Inhibiting PI3K-AKT-NF-κB Pathway.

Authors:  Cui-Li Zhang; Tao Zeng; Xiu-Lan Zhao; Ke-Qin Xie
Journal:  Int J Biol Sci       Date:  2015-04-25       Impact factor: 6.580

Review 5.  The role of the JAK-STAT pathway and related signal cascades in telomerase activation during the development of hematologic malignancies.

Authors:  Osamu Yamada; Kiyotaka Kawauchi
Journal:  JAKSTAT       Date:  2013-06-12

6.  NOD1 deficiency impairs CD44a/Lck as well as PI3K/Akt pathway.

Authors:  Yi Wei Hu; Xiao Man Wu; Shi Si Ren; Lu Cao; Pin Nie; Ming Xian Chang
Journal:  Sci Rep       Date:  2017-06-07       Impact factor: 4.379

7.  Phase I/II evaluation of RV1001, a novel PI3Kδ inhibitor, in spontaneous canine lymphoma.

Authors:  Heather L Gardner; Sarah B Rippy; Misty D Bear; Kim L Cronin; Heather Heeb; Holly Burr; Claire M Cannon; Kumar V Penmetsa; Srikant Viswanadha; Swaroop Vakkalanka; Cheryl A London
Journal:  PLoS One       Date:  2018-04-24       Impact factor: 3.240

8.  Dieckol inhibits non-small-cell lung cancer cell proliferation and migration by regulating the PI3K/AKT signaling pathway.

Authors:  Chun-Hong Wang; Xiao-Feng Li; Li-Fang Jin; Yan Zhao; Geng-Jun Zhu; Wei-Zhang Shen
Journal:  J Biochem Mol Toxicol       Date:  2019-07-10       Impact factor: 3.642

9.  Multi-parametric single cell evaluation defines distinct drug responses in healthy hematologic cells that are retained in corresponding malignant cell types.

Authors:  Muntasir M Majumder; Aino-Maija Leppä; Monica Hellesøy; Paul Dowling; Alina Malyutina; Reidun Kopperud; Despina Bazou; Emma Andersson; Alun Parsons; Jing Tang; Olli Kallioniemi; Satu Mustjoki; Peter O'Gorman; Krister Wennerberg; Kimmo Porkka; Bjørn T Gjertsen; Caroline A Heckman
Journal:  Haematologica       Date:  2019-08-22       Impact factor: 9.941

10.  Discovery of a novel phosphoinositide 3-kinase gamma (PI3Kγ) inhibitor against hematologic malignancies and theoretical studies on its PI3Kγ-specific binding mechanisms.

Authors:  Jingyu Zhu; Ke Ke; Lei Xu; Jian Jin
Journal:  RSC Adv       Date:  2019-06-28       Impact factor: 4.036

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.